91 related articles for article (PubMed ID: 22266096)
1. Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
Kimbung S; Biskup E; Johansson I; Aaltonen K; Ottosson-Wadlund A; Gruvberger-Saal S; Cunliffe H; Fadeel B; Loman N; Berglund P; Hedenfalk I
Cancer Lett; 2012 Jun; 319(2):232-241. PubMed ID: 22266096
[TBL] [Abstract][Full Text] [Related]
2. Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
Zhang H; Yu N; Chen Y; Yan K; Wang X
J Cell Biochem; 2019 Aug; 120(8):13037-13045. PubMed ID: 30873673
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
Guney Eskiler G; Ozturk M
Cell Signal; 2022 Mar; 91():110229. PubMed ID: 34958867
[TBL] [Abstract][Full Text] [Related]
4. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
5. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
6. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W
Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347
[TBL] [Abstract][Full Text] [Related]
7. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
8. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP
Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
10. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
11. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
Vazquez-Ortiz G; Chisholm C; Xu X; Lahusen TJ; Li C; Sakamuru S; Huang R; Thomas CJ; Xia M; Deng C
Breast Cancer Res; 2014 Jun; 16(3):R67. PubMed ID: 24962108
[TBL] [Abstract][Full Text] [Related]
12. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
Baloch T; López-Ozuna VM; Wang Q; Matanis E; Kessous R; Kogan L; Yasmeen A; Gotlieb WH
BMC Cancer; 2019 Jan; 19(1):44. PubMed ID: 30630446
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
[TBL] [Abstract][Full Text] [Related]
14. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
15. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
Sun Y; Ding H; Liu X; Li X; Li L
Tumour Biol; 2014 May; 35(5):4469-77. PubMed ID: 24420152
[TBL] [Abstract][Full Text] [Related]
16. Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
Wang X; Liu L; Montagna C; Ried T; Deng CX
Cell Death Differ; 2007 May; 14(5):924-31. PubMed ID: 17318223
[TBL] [Abstract][Full Text] [Related]
17. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin.
Domínguez-Gómez G; Díaz-Chávez J; Chávez-Blanco A; Gonzalez-Fierro A; Jiménez-Salazar JE; Damián-Matsumura P; Gómez-Quiroz LE; Dueñas-González A
Oncol Rep; 2015 Feb; 33(2):721-8. PubMed ID: 25504347
[TBL] [Abstract][Full Text] [Related]
19. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]